Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Pharma
ASCO: Bristol CMO brushes off LAG-3 concern after melanoma flop
Even though Opdualag failed in resected melanoma, BMS' Samit Hirawat said he’s not concerned about a more important study in metastatic lung cancer.
Angus Liu
Jun 3, 2025 8:00am
BMS’ Opdualag flunks trial as adjuvant for resected melanoma
Feb 14, 2025 8:15am
Ideaya hires Gilead leader to head up commercialization push
Nov 19, 2024 10:34am
Castle Biosciences taps ‘Real Housewife’ for melanoma awareness
Jul 23, 2024 12:23pm
ASCO: BMS' triplet, Iovance's Amtagvi-Keytruda target melanoma
May 23, 2024 5:00pm
FDA approves first T-cell therapy for a solid tumor
Feb 17, 2024 12:15pm
